Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction

Abstract

Heart failure (HF) is a global health problem inherent in an ageing population with coexisting cardiovascular diseases. Based on the data from the National Health Fund (NFZ) currently, approximately 1.2 million Polish people suffer from HF, and 140,000 of them die annually. Recently Poland was ranked 5th among the European Union countries in terms of the number of patients with diagnosed HF and 1st in terms of the number of HF hospitalizations (547 per 100,000 population) among 34 countries associated in the Organization for Economic Cooperation and Development (OECD).

History of Heart Failure in Patients Hospitalized Due to COVID-19: Relevant Factor of In-Hospital Complications and All-Cause Mortality up to Six Months

“…Approximately 64.3 million people currently live with HF, and the prevalence is estimated at 1–2% of the adult population in developed countries [ 2 , 3 ]. According to the studies of the HF Working Group of the Polish Cardiac Society based on reports of the National Health Fund, about 1.2 million people suffer from HF and 140 thousand die every year in Poland [ 4 ]. Despite the decline in cardiovascular mortality in the last decades, the prognosis in HF remains still poor.…”

Clinician’s guide for dapagliflozin use in heart failure with reduced ejection fraction

“…Experts recommend that dapagliflozin treatment should be initiated early, optimally before the hospital discharge or during a follow-up visit directly after hospital discharge following hospitalization for exacerbated HFrEF [13]. Dapagliflozin may be added to any chronic HFrEF therapy [6], including drug therapy and device therapy, and regardless of the drug doses used.…”

Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the “miraculous” sodium-glucose co-transporter-2 inhibitors?

“…Recently, there has been a vivid and ongoing discussion concerning the place of sodium--glucose co-transporter-2 (SGLT-2) inhibitors in the therapeutic management of patients with COVID-19 [2]. This drug class has an established role in the treatment of type 2 diabetes mellitus, while it has gained significant ground in the treatment armamentarium against HF, especially in patients with HF with reduced ejection fraction (HFrEF), even without concomitant type 2 diabetes mellitus [3].…”